EU/3/10/751

Table of contents

About

On 6 June 2010, orphan designation (EU/3/10/751) was granted by the European Commission to Verius Limited, United Kingdom, for synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA for the prevention of delayed graft function after renal transplantation.

This medicine is now known as teprasiran.

The sponsorship was transferred to Clinical Network Services (NL) B.V., Netherlands, in August 2019.

Key facts

Active substance
Synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA (teprasiran)
Disease / condition
Prevention of delayed graft function after renal transplantation
Date of first decision
06/06/2010
Outcome
Positive
EU designation number
EU/3/10/751

Sponsor's contact details

Clinical Network Services (NL) B.V.
De Cuserstraat 93
Amsterdam
Noord-Holland
1081 CN
The Netherlands 
E-mail: hannah.lewis@clinical.net.au

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating